Technology

A platform chemistry, not a product.

Our innovation is a foundational shift in how antimicrobial actives are produced — clean-manufactured, plant-derived, and engineered to perform across the most demanding regulated applications.

How it works

Activation, not synthesis.

Where conventional preservatives are synthesised through complex petrochemical routes, our process activates a renewable plant feedstock through a single, proprietary step — yielding a uniquely clean active ingredient with broad-spectrum performance.

Specific mechanism, formulation and process details are protected under filed patents and shared under NDA.

01

Plant-derived feedstock

Renewable vegetable glycerol — abundant, traceable, sustainable.

02

Proprietary activation

Patent-protected process unlocks novel antimicrobial behaviour.

03

Broad-spectrum

Validated activity across bacteria, viruses and persistent biofilms.

04

Favourable safety

Designed for use in regulated, sensitive and high-touch applications.

05

Cost-engineered

Manufacturing economics suited to global hygiene at scale.

06

Platform

A single chemistry, formulated across multiple sectors and use-cases.

Validation

Independently tested. Across years, not weeks.

Our claims are grounded in third-party data — including biofilm work described by the University of Glasgow as world-class.

01 / 03
3-year

Real-time stability

Three years of real-time stability data — not accelerated approximations — confirming long-term integrity of the active.

02 / 03
Kill-time

Bactericidal efficacy

Independent kill-time studies showing rapid log-reduction against industry-standard challenge organisms.

03 / 03
Antiviral

Validated activity

Third-party antiviral testing confirming activity against enveloped viral targets relevant to public health.

Full study reports available to qualified partners under NDA.

Evidence register

A structured, third-party data stack.

Independent studies spanning composition, stability, antimicrobial, antiviral, preservative-efficacy and wound-model performance — assembled to the standards expected of a regulated ingredient dossier.

Batch variability
Internal analytical (LC-MS)
Reproducible composition across production batches
Complete
Shelf-life / stability
Real-time + accelerated
36-month real-time data; multi-condition
Complete
Non-peroxide activity
Plate assay vs S. aureus
17–20% phenol-equivalent (vs <9.5 control)
Complete
MIC / MBC
CLSI M07 / M26-A
MIC 2.5% S. aureus & P. aeruginosa
Complete
Kill-time
ASTM E2783
>5-log reduction at 60 min, key organisms
Complete
Preservative efficacy
ISO 11930
Criteria A at 5%, 15% and 50% inclusion
Complete
Antiviral
EN 14476
>4-log reduction at 5 min vs enveloped virus
Complete
Biofilm / wound model
Hydrogel dressing assay
Outperformed 0.2% chlorhexidine benchmark
Preliminary

Methods, samples and full raw data disclosed to qualified partners under NDA.

Intellectual property

Patents filed across process and application.

Our IP estate covers both the proprietary activation process and its application across multiple sectors — providing a defensible foundation for partners, licensees and co-development.

Discuss under NDA →